Experiences with
Zydelig39 public posts
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
[/i]
[i]Median progression-free survival (PFS) reached 14 months with pirtobrutinib, an oral non-covalent BTK inhibitor, as compared with 8.7 months with investigator's choice of idelalisib (Zydelig) plus rituximab (Rituxan) or bendamustine (Bendeka, Treanda) plus rituximab (HR 0.54, 95% CI 0.39-0.75
Want to take advantage of all our features? Just log in!
or
Ibrutinib linked to invasive fungal infections
In the past Idelalisib (Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels.
CLL Treatment Sequencing by Dr. Susan O'Brien
O'Brien, MD
Chemotherapy is becoming less of a priority in the treatment paradigm of chronic lymphocytic leukemia (CLL) with the addition of the FDA-approved novel agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta), explained Susan M. O’Brien, MD.
Zydelig (idelalisib) first line... NO!
[/i]
[i]Limitation of Use[/i]
[i] is not indicated and is not recommended for first line treatment of patients with CLL.